-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Imago BioSciences (NASDAQ:IMGO) Stock Price Up 7.7%
Imago BioSciences (NASDAQ:IMGO) Stock Price Up 7.7%
Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) shares shot up 7.7% during trading on Friday . The stock traded as high as $15.33 and last traded at $15.32. 149 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 198,391 shares. The stock had previously closed at $14.23.
Analysts Set New Price Targets
Separately, HC Wainwright dropped their target price on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, August 16th.
Get Imago BioSciences alerts:Imago BioSciences Price Performance
The company has a market cap of $533.46 million and a PE ratio of -8.21. The stock has a fifty day moving average price of $16.04 and a 200-day moving average price of $17.41.
Insider Activity at Imago BioSciences
In other news, insider Jennifer Peppe sold 5,598 shares of the company's stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the transaction, the insider now owns 148,809 shares in the company, valued at approximately $2,888,382.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 8,168 shares of company stock valued at $155,402. Company insiders own 14.90% of the company's stock.Institutional Investors Weigh In On Imago BioSciences
A number of institutional investors have recently modified their holdings of the stock. Metropolitan Life Insurance Co NY acquired a new stake in shares of Imago BioSciences during the 1st quarter valued at about $28,000. Ameritas Investment Partners Inc. lifted its stake in Imago BioSciences by 108.3% in the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company's stock valued at $30,000 after acquiring an additional 809 shares during the last quarter. Amalgamated Bank bought a new stake in Imago BioSciences in the first quarter worth approximately $41,000. Legal & General Group Plc grew its position in Imago BioSciences by 46.2% in the second quarter. Legal & General Group Plc now owns 6,098 shares of the company's stock worth $81,000 after acquiring an additional 1,926 shares in the last quarter. Finally, Credit Suisse AG acquired a new position in shares of Imago BioSciences during the 2nd quarter worth $119,000. Institutional investors and hedge funds own 99.50% of the company's stock.
About Imago BioSciences
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
Featured Stories
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) shares shot up 7.7% during trading on Friday . The stock traded as high as $15.33 and last traded at $15.32. 149 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 198,391 shares. The stock had previously closed at $14.23.
意马生物科学公司(纳斯达克代码：IMGO-GET Rating)的股价在周五的交易中飙升了7.7%。该股盘中一度涨至15.33美元，最新报15.32美元。午盘交易中，149股股票易手，较198,391股的平均成交量下降了100%。该股此前收盘价为14.23美元。
Analysts Set New Price Targets
分析师设定新的价格目标
Separately, HC Wainwright dropped their target price on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, August 16th.
另外，在8月16日(星期二)的一份研究报告中，HC Wainwright将Imago BioSciences的目标价从36.00美元下调至35.00美元，并对该股设定了“买入”评级。
Imago BioSciences Price Performance
Imago BioSciences性价比
The company has a market cap of $533.46 million and a PE ratio of -8.21. The stock has a fifty day moving average price of $16.04 and a 200-day moving average price of $17.41.
该公司市值为5.3346亿美元，市盈率为-8.21。该股的50日移动均价为16.04美元，200日移动均价为17.41美元。
Insider Activity at Imago BioSciences
Imago BioSciences的内部活动
Institutional Investors Weigh In On Imago BioSciences
机构投资者参与Imago BioSciences
A number of institutional investors have recently modified their holdings of the stock. Metropolitan Life Insurance Co NY acquired a new stake in shares of Imago BioSciences during the 1st quarter valued at about $28,000. Ameritas Investment Partners Inc. lifted its stake in Imago BioSciences by 108.3% in the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company's stock valued at $30,000 after acquiring an additional 809 shares during the last quarter. Amalgamated Bank bought a new stake in Imago BioSciences in the first quarter worth approximately $41,000. Legal & General Group Plc grew its position in Imago BioSciences by 46.2% in the second quarter. Legal & General Group Plc now owns 6,098 shares of the company's stock worth $81,000 after acquiring an additional 1,926 shares in the last quarter. Finally, Credit Suisse AG acquired a new position in shares of Imago BioSciences during the 2nd quarter worth $119,000. Institutional investors and hedge funds own 99.50% of the company's stock.
一些机构投资者最近调整了对该股的持有量。纽约大都会人寿保险公司在第一季度收购了Imago BioSciences的新股，价值约2.8万美元。今年第一季度，ameritas Investment Partners Inc.将其在Imago BioSciences的持股比例提高了108.3%。Ameritas Investment Partners Inc.在上个季度增持了809股后，现在持有1,556股该公司股票，价值3万美元。合并银行在第一季度购买了Imago BioSciences的新股份，价值约4.1万美元。第二季度，Legal&General Group Plc在Imago BioSciences的地位增长了46.2%。Legal&General Group Plc在上个季度增持了1,926股后，现在拥有6,098股该公司股票，价值8.1万美元。最后，瑞士信贷股份公司在第二季度收购了价值11.9万美元的Imago BioSciences股票。机构投资者和对冲基金持有该公司99.50%的股票。
About Imago BioSciences
关于Imago BioSciences
(Get Rating)
(获取评级)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
临床阶段生物制药公司Imago BioSciences，Inc.发现和开发了针对赖氨酸特异性脱甲基酶1(LSD1)的小分子产品候选产品，LSD1是一种用于生产骨髓中血细胞的酶。它的主要候选产品是Bomedemstat，正在进行第二阶段临床试验，用于治疗骨髓增生性肿瘤和慢性骨髓癌，如骨髓纤维化、原发性血小板增多症和真性红细胞增多症。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- 免费获取StockNews.com关于Imago BioSciences(IMGO)的研究报告
- 霍梅尔在这些水平上看起来很便宜
- 露露柠檬将飙升至9月
- 耐克股票会被超卖，但仍被高估吗？
- 美国铝业是在第二季度业绩强劲和更多股票回购之后买入的吗？
- 皇家加勒比的宽带合作能否推动收入增长？
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Imago BioSciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧